| FNPFX | RGOIX | FNPFX / RGOIX | |
| Total Expense Ratio | 0.41 | 0.75 | 55% |
| Annual Report Gross Expense Ratio | 0.41 | 0.82 | 50% |
| Fund Existence | 9 years | 11 years | - |
| Gain YTD | 21.562 | 17.335 | 124% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 1000000 | 100000 | 1,000% |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 165B | 501M | 32,934% |
| Annual Yield % from dividends | 0.73 | 0.56 | 131% |
| Returns for 1 year | 15.05 | 13.54 | 111% |
| Returns for 3 years | 51.95 | 46.11 | 113% |
| Returns for 5 years | 35.52 | 35.29 | 101% |
| Returns for 10 years | N/A | 149.89 | - |
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| BIB | 76.07 | 0.67 | +0.88% |
| ProShares Ultra Nasdaq Biotechnology | |||
| IBRN | 29.23 | 0.16 | +0.54% |
| iShares Neuroscience and Healthcare ETF | |||
| FRDM | 48.53 | 0.19 | +0.39% |
| Freedom 100 Emerging Markets ETF | |||
| HBDC | 25.11 | 0.03 | +0.10% |
| Hilton Bdc Corporate Bond ETF | |||
| CAPE | 31.92 | N/A | +0.01% |
| DoubleLine Shiller CAPE US Equities ETF | |||